Clinical Trial Update: Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC [NA]

View source ↗

Summary

This clinical trial update reports that recruitment is ongoing for a study of the Alpha Radiation Emitters Device (DaRT) in combination with a checkpoint inhibi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Skin Cancer

Drugs mentioned

• Alpha DaRT (Alpha Radiation Emitters Device) (diffusing alpha-emitter radiation therapy device)
• Checkpoint inhibitor (unspecified)

Snippet

Sponsor: Alpha Tau Medical LTD. | Conditions: Head and Neck Squamous Cell Carcinoma, Skin Cancer | NA | Status: RECRUITING